Antidepressants and suicide
Executive Summary
FDA's analysis of independently reviewed pediatric suicidality data for antidepressants will be discussed Sept. 13-14 during a joint meeting of the Psychopharmacologic Drugs Advisory Committee and the newly formed Pediatric Advisory Committee. The meeting is a follow-up to a Feb. 2 meeting where advisory committee members expressed concern about the high degree of variability and lack of categorization of suicide-related events (1"The Pink Sheet" Feb. 9, 2004, p. 35). FDA's handling of the pediatric data has sparked Congressional inquiries. The meeting will be held at the Holiday Inn in Bethesda, Md. beginning at 8 a.m. [To 2watch a webcast or order video/DVDs of this meeting, go to FDAAdvisoryCommittee.com.]...